Jeffrey Rothman
Founding Chief Science Officer, Head Of Research & Development Oncogenuity Inc.
Dr. Rothman’s interests lie within the boundaries of organic and computational chemistry and their application towards gene control. He began studying chemistry and mathematics as an undergraduate and graduate student at MIT in the Dan Kemp group prior to a Hitchings-Elion fellowship at The Physical and Theoretical Chemistry Laboratory at Oxford University in the Graham Richards group. Returning to the US, he continued postdoctoral work at the Department of Chemistry at Columbia University as a member of the Clark Still group prior to completing medical residency. Interest in complementary DNA analogues for use in oncogene suppression followed while at Memorial Sloan-Kettering, and while an assistant professor at Columbia University Medical Center, a startup, Oncogenuity, was created based upon some of his preliminary work. Currently, he has been developing more soluble cell-penetrating peptide-PNA conjugates with better helical propensity.
Seminars
- Demonstrating near complete allele specific suppression of KRAS G12D transcription, validated by PCR and confirming precise oncogene shutdown at the source
- Intracellular delivery of oligonucleotide based therapeutics shown directly and indirectly, overcoming one of the major historical barriers for DNA analog modalities
- Debulking tumors in vivo with clear downstream RAS MAPK pathway suppression, establishing strong mechanistic to efficacy alignment in preclinical models
